PubMed COVID-19 Clinical Care

This paper applies multiple machine learning (ML) algorithms to a dataset of de-identified COVID-19 patients provided by the COVID-19 Research Database. The dataset consists of 20,878 COVID-positive patients, among which 9,177 patients died in the

With COVID-19 now pervasive, identification of high-risk individuals is crucial. Using data from a major healthcare provider in Southwestern Pennsylvania, we develop survival models predicting severe COVID-19 progression. In this endeavor, we face a

As noncontact health interventions have become critical during the Covid-19 pandemic, our study aimed to systematically review the published literature for barriers and facilitators influencing the adoption and use of remote health intervention and

Multisystem inflammatory syndrome in children (MIS-C) is a novel disease identified during the COVID-19 pandemic that may lead to cardiac dysfunction or death in pediatric patients. Early detection of MIS-C remains a challenge given the lack of a

Symbolic Regression (SR) is a data-driven methodology based on Genetic Programming, and it is widely used to produce arithmetic expressions for modelling learning tasks. Compared to other popular statistical techniques, SR outcomes are given by an

COVID-19 has caused a worldwide pandemic, accompanied by a high number of deaths and hospitalizations. Multiple preventative vaccines and variety of COVID-19 treatments have been developed and explored. This large volume of scientific work led to an

While it has been scientifically proven that COVID-19 vaccine is a safe and effective measure to reduce the severity of infection and curbing the spread of the SARS-CoV-2 virus, skepticism remains widespread, and in many countries vaccine mandates

The COVID-19 pandemic continues to be widespread, and little is known about mental health impacts from dealing with the disease itself. This retrospective study used a deidentified health information exchange (HIE) dataset of electronic health record

Data access limitations have stifled COVID-19 disparity investigations in the United States. Though federal and state legislation permits publicly disseminating de-identified data, methods for de-identification, including a recently proposed dynamic

Remdesivir has been widely used for the treatment of Coronavirus (COVID) in hospitalized patients, but its nephrotoxicity is still under investigation¹. Given the paucity of knowledge regarding the mechanism and optimal treatment of the development